The HMGXB4 Knockout A-549 Polyclonal Cells product offers a CRISPR/Cas9-mediated gene-disrupted polyclonal cell population derived from the human A-549 lung adenocarcinoma epithelial cell line. This knockout model targets HMGXB4, a gene encoding a transcriptional regulator and chromatin architectural factor, providing a powerful tool for functional genomics and cancer research. The polyclonal format ensures a heterogeneous pool of edited cells, circumventing clonal variation and enabling robust phenotypic assessments without the need for single-cell cloning. By disrupting HMGXB4, this model facilitates investigation into the gene’s role in cell proliferation, survival, and tumorigenesis.
The parental A-549 cell line was originally established from the lung adenocarcinoma tissue of a 58-year-old Caucasian male and exhibits adherent epithelial-like morphology with characteristics of type II pneumocytes. A-549 cells are widely employed as a model system for studying non-small cell lung cancer (NSCLC) due to their tumorigenic properties and well-characterized signaling networks. Their utility in cancer biology extends to investigations of oncogenic pathways, metastasis, and drug response, making them an ideal host for targeted gene disruption studies.
HMGXB4 functions as a high-mobility group (HMG) domain-containing protein that acts as a chromatin architectural factor, modulating DNA topology to facilitate transcriptional regulation. It interacts directly with ??-catenin and TCF7L2, key effectors of the Wnt/??-catenin pathway, and forms co-activator complexes with CBP/p300 and SMAD3. Upstream activation occurs through WNT ligands (e.g., WNT3A), NOTCH ligands (e.g., DLL1, JAG1), and epidermal growth factor (EGF) signaling. In turn, HMGXB4 transcriptionally regulates downstream targets including MYC, CCND1, BCL2, MMP9, and VIM, which collectively drive cell cycle progression, survival, invasion, and epithelial-mesenchymal transition. Disruption of HMGXB4 is expected to impair ??-catenin/TCF-mediated transcription, attenuating the expression of these pro-tumorigenic genes.
In the context of A-549 lung adenocarcinoma cells, HMGXB4 is likely a critical node integrating Wnt/??-catenin and Notch signaling inputs to sustain a tumorigenic phenotype. Knockout of HMGXB4 in this background provides a loss-of-function model to dissect its contribution to unchecked proliferation, apoptosis resistance, and invasive capacity. The attenuated expression of downstream effectors such as MYC and CCND1 is anticipated to reduce clonogenic growth and diminish cellular invasiveness, as measurable by colony formation and transwell migration assays. Consequently, this model enables precise dissection of HMGXB4-dependent transcriptional programs driving lung adenocarcinoma progression.
Researchers can employ the HMGXB4 Knockout A-549 Polyclonal Cells in a broad range of experimental workflows, including functional genomics, cancer biology studies, drug target validation, and signal transduction analyses. Typical assays include Western blotting and RT-qPCR to confirm gene and protein expression changes, RNA-seq for transcriptome profiling, MTT and colony formation assays for viability and proliferation assessment, and Transwell invasion/migration assays to evaluate metastatic potential. Flow cytometry and immunofluorescence can further dissect cell cycle distribution and subcellular localization of interacting factors. These cells thus serve as a versatile platform for investigating HMGXB4-mediated mechanisms in lung adenocarcinoma and for screening compounds targeting the Wnt/??-catenin or Notch pathways. For additional information or technical support, please contact Ascent Research.
